A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab Versus Doxorubicin plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma
A study for patients with advanced or metastatic soft tissue sarcoma using study drug Doxorubicin plus Olaratumab
Sponsor: Eli Lilly and Company
Enrolling: Male and Female Patients
IRB Number: AAAP8958
U.S. Govt. ID: NCT02451943
Contact: Gary Schwartz: 646-317-6041 / gks2123@columbia.edu
Additional Study Information: This study is for patients with metastatic or locally advanced soft tissue sarcoma (STS) who are not amenable to treatment with surgery or radiotherapy with curative intent. Patients will be treated with doxorubicin plus olaratumab versus doxorubicin plus placebo intravenously for 8 cycles. Patients without disease progression will be allowed to continue olaratumab or placebo monotherapy for more than 8 cycles.
This study is closed
Gary Schwartz, MD
Do You Qualify?
Do you have a confirmed diagnosis of locally advanced unresectable or metastatic soft tissue sarcoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Gary Schwartz